Annual report
4886.TEDINET S100VZL4
Period2024-04-01 → 2025-03-31
Filed2025-06-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 122
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥64.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥62.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥60.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥5.3bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥6.5bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.2bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥9.9bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥7.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥100.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥90.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥87.1bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥83.3bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥31.3bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥28.8bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥69.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥61.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥54.5bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥13.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥6.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥3.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.8bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥179.95 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥266.51 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.08 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,302.61 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,186.1 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,928.14 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,734.8 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 65.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.0% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.0% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,632 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 762 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 747 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 777 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥4.5bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥3.7bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.7bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥1.4bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥603m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥717m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥591m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥682m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥48.3bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥43.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥41.6bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥41.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.6bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥565m | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥44.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥42.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.9bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥40.7bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.4bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥111.57 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.1 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.95 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.79 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥55 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,574.11 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,506.47 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,447.55 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,443.94 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 92.5% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 28,763,199 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 80 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 75 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 79 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 74 | at 2022-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 57
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 16 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥325m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥237m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥88m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥51m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥192m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥88m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥88m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥31.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥1.3bn |
| Animal Health Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3m |
| Animal Health Businessreportable segment | employees | at 2025-03-31 | 32 pure |
| Animal Health Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Animal Health Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Animal Health Businessreportable segment | segment assets | at 2025-03-31 | ¥4.2bn |
| Animal Health Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥300m |
| Oversea Businessreportable segment | employees | at 2025-03-31 | 857 pure |
| Oversea Businessreportable segment | segment assets | at 2025-03-31 | ¥14.9bn |
| Pharmaceutical Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Pharmaceutical Businessreportable segment | employees | at 2025-03-31 | 635 pure |
| Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥56.7bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥56.7bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2025-03-31 | ¥49.6bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥64.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥64.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥88m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥68.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥6.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥226m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥162m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥64m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥39m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥125m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥201m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥64m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥64m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥42.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.2bn |
| Animal Health Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥4m |
| Animal Health Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥6.7bn |
| Animal Health Businessreportable segment | segment assets | at 2024-03-31 | ¥3.5bn |
| Animal Health Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥195m |
| Pharmaceutical Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.2bn |
| Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥56.0bn |
| Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥56.0bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2024-03-31 | ¥45.0bn |
| Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥7.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥2.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥62.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥62.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥64m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥48.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥7.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,602
| Item | Context | Value | Unit |
|---|---|---|---|
| Rate of return on equity (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.0724 | |
| Price earnings ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 53.10 | |
| Price earnings ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 56.76 | |
| Price earnings ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 25.48 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 20.65 | |
| Payout ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 0.336 | |
| Payout ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 0.764 | |
| Payout ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 0.459 | |
| Payout ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.493 | |
| Number of employees | Prior3YearInstant_NonConsolidatedMember | 74 | |
| Number of employees | Prior2YearInstant_NonConsolidatedMember | 79 | |
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 75 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 80 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | － | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.954 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.801 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.912 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.148 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.221 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.135 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 635 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 104 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E35791-000AnimalHealthBusinessReportableSegmentsMember | 32 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E35791-000AnimalHealthBusinessReportableSegmentsMember | 8 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E35791-000OverseaBusinessReportableSegmentsMember | 857 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E35791-000OverseaBusinessReportableSegmentsMember | － | |
| Number of employees | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 16 | |
| Average number of temporary workers | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 92 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 25 | |
| Number of employees | CurrentYearInstant | 1632 | |
| Average number of temporary workers | CurrentYearInstant | 137 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 80 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 46 | |
| Average age months information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 2 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 18 | |
| Average length of service months information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 8 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 9654636 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 80 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 80 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.135 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 1.000 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.693 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.743 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.668 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 6052 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 6718 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 2945 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 1813 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |